Cancer medicines
Blinatumomab
Blinatumomab
A B-cell ALL immunotherapy linking CD19 and CD3.
Sources checked · Introductory guide
On this page
How it works
A bispecific antibody bringing CD19-positive cancer cells and T cells together.[3]
Where it is used
Used in selected CD19-positive B-cell ALL according to relapse, refractory status, remission and treatment phase.[1]
Key safety points
CRS and severe neurological reactions can occur. Report fever, breathlessness, dizziness, speech trouble, confusion or seizures immediately. Confirm who to call for pump problems.[2]
Questions for your care team
- What observation or hospital plan and pump, fever or neurological contact instructions apply?
Sources and scope
Source documents are in English.
Entries summarize and translate linked official public sources. The source-check date records when those sources were checked; it does not indicate a clinician’s review.
- NCI · Blinatumomab (opens in a new tab)
- MedlinePlus · Blinatumomab (opens in a new tab)
- NCI Drug Dictionary · Blinatumomab (opens in a new tab)
General information based on official public sources. This is not a complete list of uses or side effects. Individual treatment decisions require your care team and current source documents. US-source uses do not establish local approval or reimbursement.